Chemical Engineering @ChemengFiles.Com

ProFibrix BV, has announced that it has done with the commercial license agreement with Crucell NV for PER.C6 (R), a production platform of single human protein. The platform PER.C6 (R) enables ProFibrix produce a recombinant human fibrinogen levels that support the development and commercial deployment of new products. Fibrinogen is at the heart of all ProFibrix products is an essential part of the mechanism of repair of wounds of nature. The main product of the company, Fibrocaps (TM), is based on a fibrinogen derived from human blood plasma, and is unique in a dry powder form of topical hemostatic that stops acute and severe bleeding during surgery or after a wound trauma. Initially, a recombinant fibrinogen applications will be developed for systemic hemostasis and then to develop products of
tissue repair.

Jaap Koopman, Ph.D. and CEO, commented: "The license PER.C6 (R) gives us access to manufacturing platform has already been used by ProFibrix for high expression of recombinant fibrinogen with biological activity. Our responsibility technological Doctor Bram Bout, was one of the inventors of PER.C6 (R) during their stay in Crucell. His intimate knowledge of the platform, combined with our outstanding international experience in the field of biology of fibrinogen gives us a leading position in the market for hemostasis.

Jan Ohrstrom, a physician and head of operations, said: "We believe that a recombinant fibrinogen has the potential to become a revolutionary product in the field of hemostasis and tissue repair. We intend to develop a product based on the systemic hemostasis Fibrinogen recombinants to treat or prevent bleeding in patients with low fibrinogen levels.